Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer

BACKGROUND: Evidence from randomized controlled trials (RCTs) has shown a significant survival advantage of trastuzumab. Although extant work in developed countries examined economic evaluation of trastuzumab in adjuvant treatment for early breast cancer based on the 1-year treatment, there is uncer...

Descripción completa

Detalles Bibliográficos
Autores principales: Aboutorabi, Ali, Hadian, Mohammad, Ghaderi, Hossein, Salehi, Masoud, Ghiasipour, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Canadian Center of Science and Education 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796396/
https://www.ncbi.nlm.nih.gov/pubmed/25560346
http://dx.doi.org/10.5539/gjhs.v7n1p98

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796396/
https://www.ncbi.nlm.nih.gov/pubmed/25560346
http://dx.doi.org/10.5539/gjhs.v7n1p98

Ejemplares similares